Saad, F., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N. D., Procopio, G., … Clarke, N. (2022). 1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In Annals of Oncology (Vol. 33, pp. S1160–S1160). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1945

Saad, F., A. J. Armstrong, A. Thiery-Vuillemin, M. Oya, N. D. Shore, G. Procopio, C. Arslan, et al. “1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 33:S1160–S1160. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1945.

Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore ND, Procopio G, et al. 1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: Annals of Oncology. Elsevier BV; 2022. p. S1160–S1160.

Saad, F., et al. “1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1160–S1160. Crossref, doi:10.1016/j.annonc.2022.07.1945.

Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore ND, Procopio G, Arslan C, Mehra N, Parnis F, Brown E, Constans Schlurmann F, Joung JY, Sugimoto M, Sartor O, Liu Y-Z, Poehlein CH, Desai C, Del Rosario PMD, Clarke N. 1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. Elsevier BV; 2022. p. S1160–S1160.